BIOMAT Database Logo BIOMAT Database Logo

Highly potent and selective inhibition of HIV-1 replication by 6-phenylthiouracil derivatives. 1992

M Baba, and S Shigeta, and H Tanaka, and T Miyasaka, and M Ubasawa, and K Umezu, and R T Walker, and R Pauwels, and E De Clercq
Department of Microbiology, Fukushima Medical College, Japan.

UI MeSH Term Description Entries
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013889 Thiouracil Occurs in seeds of Brassica and Crucifera species. Thiouracil has been used as antithyroid, coronary vasodilator, and in congestive heart failure although its use has been largely supplanted by other drugs. It is known to cause blood dyscrasias and suspected of terato- and carcinogenesis.
D014498 Uracil One of four nucleotide bases in the nucleic acid RNA.
D015496 CD4-Positive T-Lymphocytes A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes. T4 Cells,T4 Lymphocytes,CD4-Positive Lymphocytes,CD4 Positive T Lymphocytes,CD4-Positive Lymphocyte,CD4-Positive T-Lymphocyte,Lymphocyte, CD4-Positive,Lymphocytes, CD4-Positive,T-Lymphocyte, CD4-Positive,T-Lymphocytes, CD4-Positive,T4 Cell,T4 Lymphocyte
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse
D018894 Reverse Transcriptase Inhibitors Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. Reverse Transcriptase Inhibitor,Inhibitors, Reverse Transcriptase,Inhibitor, Reverse Transcriptase,Transcriptase Inhibitor, Reverse

Related Publications

M Baba, and S Shigeta, and H Tanaka, and T Miyasaka, and M Ubasawa, and K Umezu, and R T Walker, and R Pauwels, and E De Clercq
Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives.
February 1990, Nature,
M Baba, and S Shigeta, and H Tanaka, and T Miyasaka, and M Ubasawa, and K Umezu, and R T Walker, and R Pauwels, and E De Clercq
Highly potent and selective inhibition of bovine viral diarrhea virus replication by γ-carboline derivatives.
December 2010, Antiviral research,
M Baba, and S Shigeta, and H Tanaka, and T Miyasaka, and M Ubasawa, and K Umezu, and R T Walker, and R Pauwels, and E De Clercq
Highly potent and selective inhibition of human immunodeficiency virus type 1 by a novel series of 6-substituted acyclouridine derivatives.
June 1991, Molecular pharmacology,
M Baba, and S Shigeta, and H Tanaka, and T Miyasaka, and M Ubasawa, and K Umezu, and R T Walker, and R Pauwels, and E De Clercq
Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase.
March 1993, Proceedings of the National Academy of Sciences of the United States of America,
M Baba, and S Shigeta, and H Tanaka, and T Miyasaka, and M Ubasawa, and K Umezu, and R T Walker, and R Pauwels, and E De Clercq
Potent and selective inhibition of hepatitis C virus replication by novel phenanthridinone derivatives.
December 2011, Biochemical and biophysical research communications,
M Baba, and S Shigeta, and H Tanaka, and T Miyasaka, and M Ubasawa, and K Umezu, and R T Walker, and R Pauwels, and E De Clercq
Potent inhibition of HIV-1 replication by a Tat mutant.
November 2009, PloS one,
M Baba, and S Shigeta, and H Tanaka, and T Miyasaka, and M Ubasawa, and K Umezu, and R T Walker, and R Pauwels, and E De Clercq
TIBO derivatives: a new class of highly potent and specific inhibitors of HIV-1 replication.
May 1992, Biochemical Society transactions,
M Baba, and S Shigeta, and H Tanaka, and T Miyasaka, and M Ubasawa, and K Umezu, and R T Walker, and R Pauwels, and E De Clercq
Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase.
March 1991, Proceedings of the National Academy of Sciences of the United States of America,
M Baba, and S Shigeta, and H Tanaka, and T Miyasaka, and M Ubasawa, and K Umezu, and R T Walker, and R Pauwels, and E De Clercq
A potent and selective inhibition of parainfluenza 1 (Sendai) virus by new 6-oxiranyl-, 6-methyloxiranyluracils, and 4(3H)-pyrimidinone derivatives.
July 1998, Bioorganic & medicinal chemistry letters,
M Baba, and S Shigeta, and H Tanaka, and T Miyasaka, and M Ubasawa, and K Umezu, and R T Walker, and R Pauwels, and E De Clercq
Inhibition of HIV replication by amino-sugar derivatives.
September 1988, FEBS letters,
Copied contents to your clipboard!